From a
press release:
VIVUS, Inc. ... which recently began selling the obesity drug Qsymia
(phentermine and topiramate extended-release) capsules CIV in the United
States, today announced that its Board of Directors has appointed
Michael Astrue to serve as its Chairman and Anthony Zook to serve as its
Chief Executive Officer ...
Mr. Astrue said, "We intend to move quickly on our four main goals: 1)
expand use of Qsymia through targeted patient and physician education;
2) find the right partner for Qsymia; 3) quickly create a pathway for
approval in Europe; and 4) eliminate expenses that are not essential to
expanding use of Qsymia....
Astrue had worked in the biotechnology field before becoming Commissioner of Social Security.
1 comment:
Oh my gosh
Will the next CAL condition be obesity?
Post a Comment